Skip to content
Screener

Globus Medical GMED Reportable Segment — Other Research and Development Expense

Similar metrics at other companies

Inhibrx Biosciences, Inc. logo
INBXReportable Segment — Other Research and Development Expense
$2.91M-7.8%
Crinetics Pharmaceuticals logo
CRNXReportable Segment — Other Research and Development Expense
$8.3M+23.2%
Archer Aviation logo
ACHRReportable Segment — Other research and development expense
$133.3M+51.1%
Arvinas logo
ARVNReportable Segment — Other research and development expense
$2.4M-22.6%
Zymeworks logo
ZYMEReportable Segment — Other research and development expense
$4.66M-22.2%
Silicon Laboratories logo
SLABReportable Segment — Other research and development expenses
$56.28M+1.9%

Other financials

Income statement

See full
Revenue$789.6M+5.9%
Gross profit$548.2M+10.4%
Operating income$182.4M+140%
Net income$151.6M-25.3%
EPS (diluted)$1.10-26.2%

Balance sheet

See full
Cash & equivalents$507.7M+121%
Total debt$112.3M-7.6%
Total equity$4.8B+11.0%
Total assets$5.5B+10.6%

Cash flow

See full
Operating cash flow$209.7M+169%
CapEx$33.2M-28.8%
Free cash flow$176.6M+464%

Valuation

See full
Market cap$10.93B+52.9%
Enterprise value$10.54B+49.6%
P/E20.4×+0.4×
P/S3.5×+0.8×

Profitability

See full
Gross margin68.5%+5.8pp
Operating margin20.3%+9.6pp
Net margin17%+3.4pp
FCF margin24%+3.9pp

Returns & leverage

See full
Return on equity11.8%+3.2pp
Debt / equity0.0×
Current ratio4.6×+0.5×

Where this comes from

Reported directly by Globus Medical in its filing.

Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.

The source filing: Globus Medical’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054450
(in thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Amortization of inventory fair value step-up (a)(5,967)(6,016)
Depreciation related to cost of sales(30,934)(29,636)(62,011)(58,609)
Research and development employee-related cost(26,126)(30,101)(53,463)(55,533)
Research and development other (b)(10,194)(9,852)(19,367)(17,483)
Selling, general and administrative employee-related cost(218,357)(237,372)(445,257)(426,353)
Selling, general and administrative other (c)(55,364)(59,258)(113,797)(104,881)
Provision for litigation(62)2,621(196)3,908
Acquisition-related costs(11,080)(33,155)(17,457)(34,213)

Item 1. Financial Statements

FAQ

What is Globus Medical's reportable segment — other research and development expense?
Globus Medical (GMED) reported reportable segment — other research and development expense of $10.19M in Q2 2026.
How has Globus Medical's reportable segment — other research and development expense changed year-over-year?
Globus Medical's reportable segment — other research and development expense increased by 3.5% year-over-year, from $9.85M to $10.19M.
What does reportable segment — other research and development expense mean?
Includes non-personnel costs associated with research and development activities, such as clinical trial expenses, materials for prototypes, and external consulting fees. These costs support the development of new surgical solutions and enabling technologies.

Ask your AI about Globus Medical's reportable segment — other research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude